Affirmative
The evidence demands access
These compounds have the best treatment-resistant depression and PTSD data in a generation; scheduling them as Schedule I while fentanyl kills 100,000 Americans per year is a policy failure with a body count.
Read the affirmative case
- Phase 2 MAPS trials showed 67% of MDMA-treated PTSD patients no longer met the diagnostic criteria at 12 months, a remission rate no existing treatment approaches, and psilocybin trials at Johns Hopkins and NYU show comparable results for treatment-resistant depression.
- Psilocybin mushrooms, peyote, and ayahuasca each have a documented history of safe ceremonial and therapeutic use spanning millennia; the unknown-risk framing applies to rapid pharmaceutical commercialization, not the substances themselves.
- The FDA's 2024 rejection was based on trial-design concerns, not evidence of harm; the solution is a clear licensing pathway with rigorous therapist certification requirements, not continued prohibition of the most promising psychiatric drug class in 50 years.
